Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Open Access
- 23 January 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (2) , 385
Abstract
Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5–79.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8–64.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.Keywords
This publication has 51 references indexed in Scilit:
- Atopic dermatitisThe Lancet, 2016
- The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarizationJournal of Allergy and Clinical Immunology, 2015
- The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signalingJournal of Allergy and Clinical Immunology, 2015
- An insight into JAK-STAT signalling in dermatologyClinical and Experimental Dermatology, 2014
- Rheumatoid arthritis and cardiovascular diseaseAmerican Heart Journal, 2013
- Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990–2010: A Systematic Review of Epidemiological StudiesPLOS ONE, 2012
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- The natural course of atopic dermatitis from birth to age 7 years and the association with asthmaJournal of Allergy and Clinical Immunology, 2004
- The JAK/STAT signaling pathwayJournal of Cell Science, 2004
- The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transductionNature, 1993